Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months.
Serwanga J, Ankunda V, Sembera J, Kato L, Oluka GK, Baine C, Odoch G, Kayiwa J, Auma BO, Jjuuko M, Nsereko C, Cotten M, Onyachi N, Muwanga M, Lutalo T, Fox J, Musenero M, Kaleebu P; COVID-19 Immunoprofiling Team. Serwanga J, et al. Among authors: musenero m. Front Immunol. 2023 Mar 16;14:1152522. doi: 10.3389/fimmu.2023.1152522. eCollection 2023. Front Immunol. 2023. PMID: 37006272 Free PMC article.
Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda.
Oluka GK, Namubiru P, Kato L, Ankunda V, Gombe B, Cotten M; COVID-19 Immunoprofiling Team; Musenero M, Kaleebu P, Fox J, Serwanga J. Oluka GK, et al. Among authors: musenero m. Front Immunol. 2023 Mar 14;14:1113194. doi: 10.3389/fimmu.2023.1113194. eCollection 2023. Front Immunol. 2023. PMID: 36999017 Free PMC article.
Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy.
Serwanga J, Baine C, Mugaba S, Ankunda V, Auma BO, Oluka GK, Kato L, Kitabye I, Sembera J, Odoch G, Ejou P, Nalumansi A, Gombe B, Musenero M, Kaleebu P. Serwanga J, et al. Among authors: musenero m. Front Immunol. 2023 May 2;14:1183983. doi: 10.3389/fimmu.2023.1183983. eCollection 2023. Front Immunol. 2023. PMID: 37205095 Free PMC article.
Spike protein is a key target for stronger and more persistent T-cell responses-a study of mild and asymptomatic SARS-CoV-2 infection.
Ssali I, Mugaba S, Watelo AK, Bemanzi J, Katende JS, Oluka GK, Ankunda V, Baine C, Kato L; COVID-19 Immunoprofiling Team; Onyachi N, Muwanga M, Jjuuko M, Kayiwa J, Nsereko C, Auma BO, Weiskopf D, Sette A, Lutalo T, Musenero M, Kaleebu P, Serwanga J. Ssali I, et al. Among authors: musenero m. Int J Infect Dis. 2023 Nov;136:49-56. doi: 10.1016/j.ijid.2023.09.001. Epub 2023 Sep 6. Int J Infect Dis. 2023. PMID: 37683720 Free article.
Sustained S-IgG and S-IgA antibodies to Moderna's mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderations.
Serwanga J, Ankunda V, Katende JS, Baine C, Oluka GK, Odoch G, Nantambi H, Mugaba S, Namuyanja A, Ssali I, Ejou P, Kato L; COVID-19 Immunoprofiling Team; Musenero M, Kaleebu P. Serwanga J, et al. Among authors: musenero m. Front Immunol. 2024 Jan 31;15:1348905. doi: 10.3389/fimmu.2024.1348905. eCollection 2024. Front Immunol. 2024. PMID: 38357547 Free PMC article.
Sustained spike-specific IgG antibodies following CoronaVac (Sinovac) vaccination in sub-Saharan Africa, but increased breakthrough infections in baseline spike-naive individuals.
Sembera J, Baine C, Ankunda V, Katende JS, Oluka GK, Akoli CH, Kato L, Odoch G, Ejou P, Opio S, Musenero M; COVID-19 Immunoprofiling Team; Kaleebu P, Serwanga J. Sembera J, et al. Among authors: musenero m. Front Immunol. 2023 Nov 30;14:1255676. doi: 10.3389/fimmu.2023.1255676. eCollection 2023. Front Immunol. 2023. PMID: 38098482 Free PMC article.
COVID-19 second wave and clinical characteristics of cases in Uganda: A retrospective cross-sectional survey of confirmed SARS-CoV-2 cases, March-June 2021.
Walekhwa AW, Nakazibwe B, Nantongo M, Wafula ST, Bulafu D, Ayugi B, Nankabirwa C, Nsereko G, Nalweyiso MD, Tindyebwa T, Mayega RW, Ekiri AB, Bagenda D, Musenero M, Mugisha L. Walekhwa AW, et al. Among authors: musenero m. Epidemiol Infect. 2023 Jul 25;151:e142. doi: 10.1017/S0950268823001164. Epidemiol Infect. 2023. PMID: 37489514 Free PMC article.
The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections.
Moubarak M, Kasozi KI, Hetta HF, Shaheen HM, Rauf A, Al-Kuraishy HM, Qusti S, Alshammari EM, Ayikobua ET, Ssempijja F, Afodun AM, Kenganzi R, Usman IM, Ochieng JJ, Osuwat LO, Matama K, Al-Gareeb AI, Kairania E, Musenero M, Welburn SC, Batiha GE. Moubarak M, et al. Among authors: musenero m. Life (Basel). 2021 Jul 23;11(8):734. doi: 10.3390/life11080734. Life (Basel). 2021. PMID: 34440478 Free PMC article. Review.
Correction to: A large and persistent outbreak of typhoid fever caused by consuming contaminated water and street-vended beverages: Kampala, Uganda, January - June 2015.
Kabwama SN, Bulage L, Nsubuga F, Pande G, Oguttu DW, Mafigiri R, Kihembo C, Kwesiga B, Masiira B, Okullo AE, Kajumbula H, Matovu JK, Makumbi I, Wetaka M, Kasozi S, Kyazze S, Dahlke M, Hughes P, Sendagala JN, Musenero M, Nabukenya I, Hill VR, Mintz E, Routh J, Gómez G, Bicknese A, Zhu BP. Kabwama SN, et al. Among authors: musenero m. BMC Public Health. 2017 Oct 18;17(1):823. doi: 10.1186/s12889-017-4801-y. BMC Public Health. 2017. PMID: 29047373 Free PMC article. No abstract available.
24 results